Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 7, 2003, Pages 2193-2198

  Keith, Kathy A ^a   Hitchcock, Michael J M ^b   Lee, William A ^b   Holý, Antonin ^c   Kern, Earl R ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b GILEAD SCIENCES   (United States)

^c INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; CIDOFOVIR; GS 0573; GS 0577; GS 0930; GS 17432; GS 3857; GS 4331; GS 7340; GS 7356; GS 7357; GS 7358; GS 8262; GS 8357; GS 8361; GS 8367; GS 8368; GS 8369; GS 8370; NUCLEOSIDE DERIVATIVE; PRODRUG; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; COWPOX VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS INHIBITION; VIRUS REPLICATION;

ADENINE; ANTIVIRAL AGENTS; CELLS, CULTURED; CYTOSINE; HUMANS; ORGANOPHOSPHORUS COMPOUNDS; ORTHOPOXVIRUS; PHOSPHONIC ACIDS; POXVIRIDAE INFECTIONS; PRODRUGS; SKIN; VIRUS REPLICATION;

EID: 0038312076     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.7.2193-2198.2003     Document Type: Article

References (36)

1. Baker, R. O., M. Bray, and J. W. Huggins. 2002. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antivir. Res. 57:13-23.
2. Ballatore, C., C. McGuigan, E. De Clercq, and J. Balzarini. 2001. Synthesis and evaluation of novel amidate prodrugs of PMEA and PMPA. Bioorg. Med. Chem. Lett. 11:1053-1056.
3. Balzarini, J., S. Aquaro, C.-F. Perno, M. Witvrouw, A. Holý, and E. De Clercq. 1996. Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems. Biochem. Biophys. Res. Commun. 219:337-341.
4. Barditch-Crovo, P., J. Toole, C. W. Hendrix, K. C. Cundy, D. Ebeling, H. S. Jaffe, and P. S. Lietman. 1997. Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonyl-methoxyethyl]adenine) in HIV-infected patients. J. Infect. Dis. 176:406-413.
5. Barditch-Crovo, P., S. G. Deeks, A. Collier, S. Safrin, D. F. Coakley, M. Miller, B. P. Kearney, R. L. Coleman, P. D. Lamy, J. O. Kahn, I. McGowan, and P. S. Lietman. 2001. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. 45:2733-2739.
6. Beadle, J. R., C. Hartline, K. A. Aldern, N. Rodriguez, E. Harden, E. R. Kern, and K. Y. Hostetler. 2002. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob. Agents Chemother. 46:2381-2386.
7. Bray, M., M. Martinez, D. F. Smee, D. Kefauver, E. Thompson, and J. W. Huggins. 2000. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J. Infect. Dis. 181:10-19.
8. Bray, M., M. Martinez, D. Kefauver, M. West, and C. Roy. 2002. Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir. Antivir. Res. 54:129-142.
9. Breman, J. G., and I. Arita. 1980. The confirmation and maintenance of smallpox eradication. N. Engl. J. Med. 303:1263-1273.
10. Breman, J. G., and D. A. Henderson. 1998. Poxvirus dilemmas-monkeypox, smallpox, and biologic terrorism. N. Engl. J. Med. 339:556-559.
11. Chapman, H., M. Kernan, E. Prisbe, J. Rohloff, M. Sparacino, T. Terhorst, and R. Yu. 2001. Practical synthesis, separation, and stereochemical assignment of the PMPA pro-drug GS-7340. Nucleosides Nucleotides Nucleic Acids 20:621-628.
12. Chapman, H., M. Kernan, J. Rohloff, M. Sparacino, and T. Terhorst. 2001. Purification of PMPA amidate prodrugs by SMB chromatography and x-ray crystallography of the diastereomerically pure GS-7340. Nucleosides Nucleotides Nucleic Acids 20:1085-1090.
13. Cihlar, T., G. Birkus, D. E. Greenwalt, and M. J. M. Hitchcock. 2002. Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. Antivir. Res. 54:37-45.
14. Cundy, K. C. 1999. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin. Pharmacokinet. 36:127-143.
15. De Clercq, E., M. Luczak, D. Shugar, P. F. Torrence, J. A. Waters, and B. Witkop. 1976. Effect of cytosine, arabinoside, iododeoxyuridine, ethyldeoxyuridine, thiocyanatodeoxyuridine, and ribavirin on tail lesion formation in mice infected with vaccinia virus. Proc. Soc. Exp. Biol. Med. 151:487-490.
16. De Clercq, E., T. Sakuma, M. Baba, R. Pauwels, J. Balzarini, I. Rosenberg, and A. Holý. 1987. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antivir. Res. 8:261-272.
17. De Clercq, E. 1993. Antivirals for the treatment of herpesvirus infections. J. Antimicrob. Chemother. 32:121-132.
18. De Clercq, E. 1997. Acyclic nucleoside phosphonates in the chemotherapy of DNA virus and retrovirus infections. Intervirology 40:295-303.
19. De Clercq, E. 2001. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clin. Microbiol. Rev. 14:382-397.
20. Gorschlüter, M., C. Ziske, A. Glasmacher, and I. G. H. Schmidt-Wolf. 2001. Current clinical and laboratory strategies to augment the efficacy of immunotherapy in multiple myeloma. Clin. Cancer Res. 7:2195-2204.
21. Guerguerian, A.-M., M. Gauthier, M. H. Lebel, C. A. Farrell, and J. Lacroix. 1999. Ribavirin in ventilated respiratory syncytial virus bronchiolitis. Am. J. Respir. Crit. Care Med. 160:829-834.
22. 6-substituted adenines, -2,6-diaminopurines and related compounds. Collect. Czech. Chem. Commun. 66:1545-1592.
23. Hutin, Y. J. F., R. J. Williams, P. Malfait, R. Pebody, V. N. Loparev, S. L. Ropp, M. Rodriguez, J. C. Knight, F. K. Tshioko, A. S. Khan, M. V. Szczeniowski, and J. J. Esposito. 2001. Outbreak of human monkeypox, Democratic Republic of Congo, 1996 to 1997. Emerg. Infect. Dis. 7:434-438.
24. Kern, E. R., C. Hartline, E. Harden, K. Keith, N. Rodriguez, J. R. Beadle, and K. Y. Hostetler. 2002. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob. Agents Chemother. 46:991-995.
25. Kern, E. R. 2003. In vitro activity of potential anti-poxvirus agents. Antivir. Res. 57:35-40.
26. Lalezari, J. P., R. J. Stagg, B. D. Kuppermann, G. N. Holland, F. Kramer, D. V. Ives, M. Youle, M. R. Robinson, W. L. Drew, and H. S. Jaffe. 1997. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann. Intern. Med. 126:257-263.
27. Meier, P., S. Dautheville-Guibal, P. M. Ronco, and J. Rossert. 2002. Cidofovir-induced end-stage renal failure. Nephrol. Dial. Transplant. 17:148-149.
28. Naesens, L., R. Snoeck, G. Andrei, J. Balzarini, J. Neyts, and E. De Clercq. 1997. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antivir. Chem. Chemother. 8:1-23.
29. Neyts, J., and E. DeClercq. 1993. Efficacy of (S)-1-(3-hydroxy-2-phosphonyl methoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. J. Med. Virol. 41:242-246.
30. Oliyai, R., M. N. Arimilli, R. J. Jones, and W. A. Lee. 2001. Pharmacokinetics of salicylate ester prodrugs of cyclic HPMPC in dogs. Nucleosides Nucleotides Nucleic Acids 20:1411-1414.
31. Reichard, O., J. Andersson, R. Schvarcz, and O. Weiland. 1991. Ribavirin treatment for chronic hepatitis C. Lancet 337:1058-1061.
32. Safrin, S., J. Cherrington, and H. S. Jaffe. 1999. Cidofovir. Review of current and potential clinical uses. Adv. Exp. Med. Biol. 458:111-120.
33. Smee, D. F., K. W. Bailey, M. Wong, and R. W. Sidwell. 2000. Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir. Antivir. Res. 47:171-177.
34. Smee, D. F., K. W. Bailey, and R. W. Sidwell. 2001. Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir. Antivir. Chem. Chemother. 12:71-76.
35. Snoeck, R., A. Holý, C. Dewolf-Peeters, J. Van Den Oord, E. De Clercq, and G. Andrei. 2002. Antivaccinia activities of acyclic nucleoside phosphonate derivatives in epithelial cells and organotypic cultures. Antimicrob. Agents Chemother. 46:3356-3361.
36. Yokota, T., S. Mochizuki, K. Konno, S. Mori, S. Shigeta, and E. De Clercq. 1991. Inhibitory effects of selected antiviral compounds on human hepatitis B virus DNA synthesis. Antimicrob. Agents Chemother. 35:394-397.